Convenient one-step synthesis of a medicinally relevant benzopyranopyridine system

Tetrahedron Letters

Volumn 47, Issue 52, 2006, Pages 9309-9312

  Evdokimov, Nikolai M ^a   Kireev, Artem S ^b   Yakovenko, Andrey A ^c   Antipin, Mikhail Yu ^c,d   Magedov, Igor V ^a,e   Kornienko, Alexander ^b  

^a RUSSIAN STATE AGRARIAN UNIVERSITY   (Russian Federation)

^b NEW MEXICO INSTITUTE OF MINING AND TECHNOLOGY   (United States)

^c NEW MEXICO HIGHLANDS UNIVERSITY   (United States)

^d A N NESMEYANOV INSTITUTE OF ORGANOELEMENT COMPOUNDS   (Russian Federation)

^e Intelbioscan Ltd   (Russian Federation)

Author keywords

Drug like heterocycle; Multicomponent reaction; Privileged medicinal scaffold

Indexed keywords

ALDEHYDE DERIVATIVE; BENZOPYRAN DERIVATIVE; MALONONITRILE; PYRIDINE DERIVATIVE; THIOL DERIVATIVE;

ARTICLE; CHEMICAL PROCEDURES; CHEMICAL REACTION; DRUG SYNTHESIS; REACTION ANALYSIS;

EID: 33751192438     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2006.10.110     Document Type: Article

References (29)

1. For recent reviews, see:. Gerencsér J., Dormán G., and Darvas F. QSAR Comb. Sci. (2006) 439-448
2. Ramón D.J., and Yus M. Angew. Chem., Int. Ed. 44 (2005) 1602-1634
3. Orru R.V.A., and de Greef M. Synthesis (2003) 1471-1499
4. Hulme C., and Gore V. Curr. Med. Chem. 10 (2003) 51-80
5. Ugi I., and Heck S. Comb. Chem. High Throughput Screen 4 (2001) 1-34
6. Weber L., Illgen K., and Almstetter M. Synlett (1999) 366-374
7. The term 'privileged scaffolds or structures' was originally introduced by Merck researchers in their work on benzodiazepines:. Evans B.E., Rittle K.E., Bock M.G., DiPardo R.M., Freidinger R.M., Whitter W.L., Lundell G.F., Veber D.F., Anderson P.S., Chang R.S.L., Lotti V.J., Cerino D.J., Chen T.B., Kling P.J., Kunkel K.A., Springer J.P., and Hirshfield J. J. Med. Chem. 31 (1988) 2235-2246
8. For a review, see:. Patchett A.A., and Nargund R.P. Ann. Rep. Med. Chem. 35 (2000) 289-298
9. Kolokythas G., Pouli N., Marakos P., Pratsinis H., and Kletsas D. Eur. J. Med. Chem. 41 (2006) 71-79
10. Azuine M.A., Tokuda H., Takayasu J., Enjyo F., Mukainaka T., Konoshima T., Nishino H., and Kapadia G.J. Pharmacol. Res. 49 (2004) 161-169
11. Srivastava S.K., Tripathi R.P., and Ramachandran R. J. Biol. Chem. 280 (2005) 30273-30281
12. Brötz-Oesterhelt H., Knezevic I., Bartel S., Lampe T., Warnecke-Eberz U., Ziegelbauer K., Häbich D., and Labischinski H. J. Biol. Chem. 278 (2003) 39435-39442
13. Toshiro, S.; Noriko, W. Eur. Pat. Appl. EP 647445 A1 19950412, 1995.
14. Ito, Y.; Kato, H.; Yasuda, S.; Kato, N.; Iwasaki, N.; Nishino, H.; Takeshita, M. Jpn. Kokai Tokkyo Koho, JP 06107664 A2 19940419, 1994.
15. Goto, K.; Yaoka, O.; Oe, T. PCT Int. Appl. WO 8401711 A1 19840510, 1984.
16. Maruyama, Y.; Goto, K.; Terasawa, M. Ger. Offen. DE 3010751 19810806, 1981.
17. Ukawa K., Ishiguro T., Kuriki H., and Nohara A. Chem. Pharm. Bull. 33 (1985) 4432-4437
18. For recent synthetic work, see:. Abdel-Rahman A.H., Hammouda M.A.A., and El-Desoky S.I. Heteroat. Chem. 16 (2005) 20-27
19. Langer P., and Appel B. Tetrahedron Lett. 44 (2003) 5133-5135
20. Daia D.E., Gabbutt C.D., Heron B.M., Hepworth J.D., Hursthouse M.B., and Abdul Malik K.M. Tetrahedron Lett. 44 (2003) 1461-1464
21. Fujiwara H., and Kitagawa K. Heterocycles 53 (2000) 409-418
22. O'Callaghan C.N., McMurry T.B.H., O'Brien J.E., and Draper S.M. J. Chem. Res. (S) (1997) 312-313
23. O'Callaghan C.N., McMurry T.B.H., and O'Brien. J. Chem. Soc., Perkin Trans. 1 (1995) 417-420
24. Anderson D.R., Hegde S., Reinhard E., Gomez L., Vernier W.F., Lee L., Liu S., Sambandam A., Snider P.A., and Masih L. Bioorg. Med. Chem. Lett. 15 (2005) 1587-1590
25. Bristol J.A., Gold E.H., Gross I., Lovey R.G., and Long J.F. J. Med. Chem. 24 (1981) 1010-1013
26. Evdokimov N.M., Magedov I.V., Kireev A.S., and Kornienko A. Org. Lett. 8 (2006) 899-902
27. 2 (all data) = 0.1037. Supplementary data in the form of CIFs have been deposited with the Cambridge Crystallographic Data Centre (CCDC 622796). Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 1223 336033 or e-mail: deposit@ccdc.cam.ac.uk].
28. 3N (0.1 mmol) dropwise at room temperature. The resulting mixture was refluxed for 3-3.5 h and then allowed to cool to room temperature. The formed precipitate was isolated by filtration. The product was dissolved in DMF (3 mL), and the remaining undissolved material was removed by filtration. To the filtrate was added water (4 mL), which resulted in the crystallization of the product. The formed crystals were isolated by filtration to yield a corresponding pure benzopyranopyridine (1-11).
29. 2S (376.442): C, 63.81; H, 4.29; N, 14.89; S, 8.52. Found: C, 63.95; H 4.08; N, 14.81; S, 8.63.